New FDA approvals and emerging trial data drive two pivotal 2026 NCCN guideline updates: lutetium-177 PSMA-617 for ...

Collapsing the very-low-risk category reflects broader acceptance of active surveillance for Gleason 6 disease, while PARP ...

Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of these men will die of causes other than prostate cancer. This is revealed in a ...

Up to 5,000 men a year could avoid potentially harmful treatment for prostate cancer if ‘outdated’ guidelines reflected the latest evidence, a charity has said. Closely monitoring the disease with ...

It does if a single state in the U.S. is any indication. In North Carolina, significantly higher rates of prostate cancer recurrence were reported among men living in rural areas compared to their ...

People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...

Patients with nonmetastatic prostate cancer are more likely to die from other causes than from cancer when treated per guidelines. The 15-year cancer mortality risk is 5.5% for low-risk and 22% for ...

Risk of death and cause of death 30 years after diagnosis as a proportion of 100 men. Grey figures indicate the proportion of men alive after 30 years, blue figures the proportion of men who died of ...

If your cancer is not causing any symptoms, is growing slowly, or is small and only in your prostate, your physician may suggest active surveillance or watchful waiting instead of treatment. Active ...